Search
Metaxalone
go.drugbank.com/drugs/DB00660ApprovedInvestigationalMetaxalone is associated with few side effects and is available as a 800 mg scored tablet. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.
Tolvaptan
go.drugbank.com/drugs/DB06212ApprovedInvestigationalTolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Garenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Topoisomerase II InhibitorsXR5944
go.drugbank.com/drugs/DB06364ExperimentalXR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalThe drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].
Dicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Synonyms: (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidProducts: DICLOXACILINA 125 MG / 5 ML, DICLOCIL SUSPENSION ORAL 250 MG/5 MLRP01
go.drugbank.com/drugs/DB05751ExperimentalIt is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … RP01 is a novel anti-IgE immunotherapy for allergic individuals.